Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$22.17 - $51.8 $130,803 - $305,620
5,900 New
5,900 $305,000
Q4 2021

Feb 14, 2022

BUY
$18.38 - $40.5 $108,442 - $238,950
5,900 New
5,900 $215,000

Others Institutions Holding CCXI

About ChemoCentryx, Inc.


  • Ticker CCXI
  • Exchange NASDAQ
  • Shares Outstandng 71,919,696
  • Market Cap $3.68M
  • Description
  • ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...
More about CCXI
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.